Cleared Traditional

K121610 - COBAS C 501 TINA-QUANT HBA1CDX GEN.3 ASSAY

K121610 is the FDA 510(k) clearance for COBAS C 501 TINA-QUANT HBA1CDX GEN.3 ASSAY by Roche Diagnostics Operations. It is a Class 2 Chemistry device (product code PDJ) cleared through the Traditional 510(k) pathway after a 433-day FDA review.

K121610 · Roche Diagnostics Operations · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2013
Decision
433d
Days
Class 2
Risk

K121610 is an FDA 510(k) clearance for the COBAS C 501 TINA-QUANT HBA1CDX GEN.3 ASSAY. Classified as Hemoglobin A1c Test System (product code PDJ), Class II - Special Controls.

Submitted by Roche Diagnostics Operations (Indianapolis, US). The FDA issued a Cleared decision on August 8, 2013 after a review of 433 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1373 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Chemistry submissions.

View all Roche Diagnostics Operations devices

Submission Details

510(k) Number K121610 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 01, 2012
Decision Date August 08, 2013
Days to Decision 433 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
345d slower than avg
Panel avg: 88d · This submission: 433d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code PDJ Hemoglobin A1c Test System
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1373
Definition Quantitative Determination Of Hemoglobin A1c To Aid In The Diagnosis Of Diabetes.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - PDJ Hemoglobin A1c Test System

All 21
Devices cleared under the same product code (PDJ) and FDA review panel - the closest regulatory comparables to K121610.
Hemoglobin A1c Assay, Hemoglobin A1c Calibrators, Hemoglobin A1c Controls
K140654 · Abbott Laboratories · May 2015
VARIANT II TURBO HbA1c Kit - 2.0
K142448 · Bio-Rad Laboratories, Inc. · Mar 2015
HEMOGLOBIN A1C, HEMOGLOBIN A1C CALIBRATORS, HEMOGLOBIN A1C CONTROLS
K130255 · Abbott Laboratories · Feb 2014
TINA-QUANT HBA1C GEN. 2 TEST SYSTEM
DEN130002 · Roche Diagnostics · May 2013